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TrimethoprimA B S T R A C T
Background: Dihydrofolate reductase (DHFR) (dfrA gene) is an essential enzyme for cell sur-
vival and an unexplored target in Mycobacterium tuberculosis (Mtb). This study was carried
out to analyze mutations in the dfrA gene amongst 20 clinical DNA samples from Mtb iso-
lates obtained from Mumbai, India.
Methods: Sequencing of the PCR amplified dfrA gene from these DNA isolates revealed a
point mutation in one strain, leading to a glutamic acid to glycine change. In silico sim-
ulation studies revealed a surface alteration in the enzyme due to this E84G mutation.
The amplified mutant gene was cloned and expressed. The mutant protein was assessed
against known DHFR inhibitors: Methotrexate and Trimethoprim.
Results: An increased affinity for inhibitor Trimethoprim and native substrate dihydrofo-
late was observed with the mutant. Methotrexate did not vary in its activity with both
the enzyme forms.
Conclusions: The Glu84Gly point mutation may lead to a variation in the strain which may
cause resistance in the future.
 2015 Asian African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.Introduction
Biosynthesis of a variety of cellular components involves the
presence of reduced folates in both prokaryotes and eukary-
otes. The normal mechanism of synthesis involves de novo
biosynthesis along with salvage pathways in some bacteria
and mammalian cells. Dihydrofolate reductase (DHFR)(encoded by dfrA gene) has an essential role in the mainte-
nance of cellular pools of reduced folate, tetrahydrofolate
(THF) and its derivatives, including methylation of dUMP to
dTMP, and in cell growth and proliferation. The enzyme is
hence a target for several anti-bacterial and anti-cancer
agents [1,2]. Thymidylate synthase (TS) is the enzyme which
functions downstream of DHFR in the folate pathway. Two
98 I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 4 ( 2 0 1 5 ) 9 7 –1 0 3forms of TS enzyme coexist in Mycobacterium tuberculosis
(Mtb), namely ThyA and ThyX [3]. ThyA is involved in de novo
synthesis, while ThyX functions as a Pyrimidine Salvage
Pathway enzyme. The conversion of dUMP to dTMP, carried
out by both forms of thymidylate synthase, requires the pres-
ence of tetrahydrofolate, which is formed due to the activity
of DHFR enzymes. Thus, an inhibited DHFR enzyme would
result in the accumulation of dUMP, which would get con-
verted to dUTP, and the incorporation of dUTP into DNA
results in cell death [4].
Mtb, a human pathogen, claims more lives than any other
known infectious organism around the world [5,6]. The cur-
rent therapy involves a four-drug regime [7–9]. However, due
to the emergence of multi-drug resistant (MDR) forms of the
organism, the current treatment proves inefficient [10]. A
sequence alignment of human and Mtb DHFRs indicates only
26% sequence identity [11]. However, mutations in this target
may disrupt the inherent binding ability of this enzyme to
known inhibitors. Hence, the present study was undertaken
to investigate 20 clinical isolates of first-line drug-resistant
tuberculosis (TB) for inherent mutations in the dfrA gene.
The studies led to the identification of a point mutation
replacing Adenine by Guanine at the 251st position in the
dfrA gene (480 bp) of one of the 20 screened isolates. This leads
to an amino acid change of glutamic acid to glycine at the 84th
position of the enzyme. Docking software was employed to
locate the position of this alteration to the surface of the pro-
tein. Thus, it was assumed that the modification would not
alter the interaction directly at the active site, but might
allosterically or structurally affect it. This was in accordance
with the fact that DHFR is an essential enzyme, and the organ-
ismmight not mutate in a manner to affect its inherent func-
tion in order to maintain its own viability.
The mutated gene was cloned and expressed using pET21a
vector. The expressed protein was assessed using SDS–PAGE
and Km determination for native substrate, dihydrofolate
(DHF). The mutant was also screened against known inhibi-
tors of DHFR, Trimethoprim (TMP) and Methotrexate (MTX),
by both in silico docking studies and in vitro enzyme assay.
The results obtained indicate better binding of the mutant
enzyme with the substrate, DHF and inhibitor, TMP when
compared with the wild type.
Materials and methods
Chemicals and standard drugs
DHF was purchased from Sigma Aldrich. MTX was obtained
as a gift sample from Khandelwal Laboratories Pvt. Ltd.,
Mumbai, India. TMP, buffer salts, reduced nicotinamide ade-
nine dinucleotide phosphate (NADPH) and Dithiothreitol
(DTT) were purchased from HiMedia.
Amplification of dfrA gene from 20 clinical isolates
The chromosomal DNA of 20 clinical isolates was procured
from RMC-BARC, Mumbai, India. The primary source of these
strains was Sewri Tuberculosis Hospital, Mumbai, India. The
genomic DNA was extracted from all the strains by the stan-
dard cetyl trimethyl ammonium bromide (CTAB) method [12].These strains were selected based on their resistance against
first-line drugs identified by employing the recommended
WHO protocol [13]. Out of these isolated strains, 3 were resis-
tant to Isoniazid, 12 to Rifampicin, 3 others to Isoniazid and
Rifampicin, and 2 were resistant to Isoniazid, Rifampicin
and Streptomycin. The drug susceptibility was performed by
the standard proportion method as described in Standard
Operating Protocol (SOP) prepared in the Revised National
TB Control Programme Training Manual for ‘‘Mycobacterium
tuberculosis Culture & Drug susceptibility testing’’. The docu-
ment was prepared by the Central TB Division, Directorate
General of Health Services, Ministry of Health and Family
Welfare Government of India. Along with these DNA samples,
the wild type Mtb H37Rv DNA sample was also procured as a
standard. The complete dfrA gene (480 bp) was amplified from
these isolates and standard using the forward primer 5P-GAC
GCG TGTGCATAT GGT GGG GCT GAT CTG-3P and reverse pri-
mer 5P-GCG ATG AGG ATC CGC GGC GCT CATGAG CGG-3P,
containing NdeI and BamHI restriction sites, respectively [14].
The amplified fragments were checked on agarose gel and
sequenced by employing dideoxy DNA sequencing method
of Sanger et al. using ABI Prism 377-18 automated DNA
sequencer and the Big Dye terminator kit (ABI, Foster City,
CA). A point mutation was found in one of the 20 isolates.
In silico mutation analysis
The ligands (Methotrexate and Trimethoprim) were sketched
using the 2D-sketcher of Maestro (GLIDE, Schro¨dinger 9.0,
LLC, NY). Low-energy 3D structures of ligands were generated
with the help of Ligprep, by adding appropriate hydrogens,
generating possible ionization states and tautomers. The
ligands were subsequently subjected to energy minimization
using the OPLS-2005 force field.
The protein structure PDB code: 1DG8which is the complex
of Mtb DHFR enzyme and NADPH with resolution of 2.00 was
retrieved from Brookhaven Protein Data Bank (www.rcsb.com)
and used for validation of the docking algorithm. All water
molecules were deleted, bond orders and charges of cofactor
NADPH were assigned properly in the protein preparation
step. The amino acid at the 84th position was altered to gener-
ate the mutant enzyme. The docking study was carried out
using GLIDE software in both standard precision (SP) and extra
precision (XP) mode with ‘must match’ of at least one hydro-
gen bond criteria; with Ile5, Asp27 and Ile94 (10) using both
the wild type and the mutant protein structure.
Cloning, expression and purification of the mutant identified
The mutant amplified fragment was cleaned using the
QIAquick PCR purification kit (Qiagen). Both the amplified
dfrA gene and pET21a expression vector (Novagen) were then
digested with NdeI and BamHI, purified on a 1.0% agarose gel,
eluted, and ligated together using T4 DNA ligase overnight at
room temperature (20 C). The resulting construct was
sequenced to confirm that the dfrA genewas in the proper ori-
entation for expression and that no other mutations were
introduced during the PCR amplification. After propagation in
Escherichia coli strainDH5a, the constructwaspurifiedand trans-
formed into E. coli strain BL21 STAR (Invitrogen) for expression.
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T7 promoter in recombinant E. coli BL21 cells. Briefly, the
recombinant cells were grown in Luria-Bertani (LB) medium
(HiMedia) at 37 C until optical density (OD600) reached 0.4–
0.5. Induction was performed by the addition of 1 mM iso-
propyl-L-thiogalactopyranoside (IPTG), and cells were grown
for two and half hours more at 37 C to reach an OD of 1.5.
Cells were centrifuged, washed with cold phosphate-buffered
saline (PBS) and the pellet frozen at 80 C. The pellet was
thawed and used for enzyme purification using Ni-IDA
(Nickel-Iminodiacetic acid) column comprising of
Sephabeads IP-IDA resin and urea and imidazole as eluents.
The purified enzyme, obtained from the pellet after column
chromatography, was analyzed using SDS–PAGE and
characterized by Km determination for substrate dihydrofo-
late (DHF).
IC50 determination using enzyme assay
The mutant DHFR activity was determined spec-
trophotometrically against known ligands MTX and TMP by
monitoring the decreasing absorbance for 2 min at 340 nm
and 37 C. Standard assay mixture contained 50 mM KPO4
(pH 7.4), 5 mM DTT, and 60 lM NADPH, and the reaction was
started after a 3 min incubation by the addition of 45 lM
DHF [14,15]. The wild type enzyme obtained after optimized
purification from recombinant yeast [16–18] was used as the
control DHFR for the studies. The wild type and mutant
enzymes were characterized by determining Km values for
the substrate DHF using MS Excel graph plots.
The inhibitors MTX and TMP were used in the reaction
mixtures in 5 different concentrations. The assay was carried
out in microtiter plates in duplicates in the assay and ana-
lyzed using the kinetic mode of the micro plate reader from
Synergy H1 BioTek with Gen5 software. The Inhibitory con-
centration 50 (IC50) values were determined from graph plots
generated by MS Excel and standard deviation was calculated.Figure 1 – Overlap of wild type (pink) and mutant (green) DHFR
amino acid residue.Results
The amplified dfrA gene of the 20 clinical isolates and the
standard Mtb H37Rv were analyzed on agarose gel where
480 bp sequences were visualized. These amplified genes
were sequenced and the sequencing revealed a point muta-
tion in isolate number 19 which was absent in the wild type
H37Rv strain when analyzed using Serial cloner 2.5 (alignment
tool, sequence aligned with Mtb DHFR with GenBank acces-
sion number NC_000962). A transition from Adenine to
Guanine at position 251 in the dfrA gene of an isolate, which
was resistant to Isoniazid, Rifampicin and Streptomycin (MIC
at concentrations of 0.2 lg/ml for Isoniazid, 40 lg/ml for
Rifampicin and 4 lg/ml for Streptomycin), led to the iden-
tification of an alteration of amino acid at the 84th position
(glutamic acid to glycine) which was found to result in a sur-
face modification (slightly unaligned b sheet from amino acid
79 to 85) through in silico simulation studies (Fig. 1). This
might be the result of a change in surface charge from nega-
tive to neutral. Hence the interaction with the nearby side
chain is minimized thereby resulting in distancing of the
entire b sheet.
As a result of the in silico studies, it was revealed that the
known inhibitors MTX and TMP interacted with the wild type
and the mutant differently (Table 1-Docking scores). MTX
showed complete alignment in the docked images of wild
type as well as mutant since the slight alignment variation
did not cause any contact changes within the active site
(Fig. 2). However, TMP showed altered and, curiously, a better
docking score with the mutant than the wild type which is
supported by the change in alignment of TMP in the active
site of mutant as depicted in Fig. 3. Also, any alteration in
the Mtb DHFR surface geometry has been reported to affect
the final binding of TMP in the active site as reported by
Nerukh et al. [19]. Hence, this surface modification could have
led to the differential binding of TMP in the active site pocket
of the mutant enzyme.enzyme depicting area of surface modification around 84th
Table 1 – In silico Docking scores and in vitro IC50 values of wild type and mutant Mtb DHFR with MTX and TMP.
Ligand Wild type DHFR Mutant DHFR
Docking Score IC50 (lM) Docking Score IC50 (lM)
MTX 9.38 0.008 ± 0.0007 9.38 0.008 ± 0.0004
TMP 4.43 16.0 ± 3.0 6.60 10.5 ± 2.0
Figure 2 – Interaction diagram of DHFR enzyme with MTX (orange) (a) with 8 A˚ surface generated for wild type (pink) and (b)
with mutant (green) (c) Ligplot of MTX with wild type (6 A˚) (d) Ligplot of MTX with mutant (6 A˚).
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with the mutant gene insert was prepared and purified. The
new construct (pET21a-MtbDHFR#19) was transformed in E.
coli BL21 and later used for protein expression. Purification
of the Mtb DHFR using the Ni-IDA column was confirmed
using the SDS–PAGE which revealed a 19 kDa protein band.
Formation of inclusion bodies in the E. coli host leads to
enzyme loss. Since this issue was not encountered, the puri-
fied enzymewas considered for further studies. The wild type
enzyme was purified from recombinant yeast. A comparative
study of the two enzymes was undertaken since both were
obtained in pure form.The enzymes were characterized by Km determination and
assessed for activity against the ligands MTX and TMP. The
Km value of the mutant enzyme (4.4 ± 0.02 lM) is slightly less
than the Km value for the wild type enzyme (4.6 ± 0.05 lM)
indicating that the mutant has a slightly higher affinity
towards the substrate DHF.
The comparative wild type andmutant enzyme IC50 values
are as shown in Table 1. When the IC50 values were
compared with the reported IC50 of the wild type [15], the
mutant shows a visibly better interaction with TMP as indi-
cated by the docking studies thus validating the in silico
obtained results.
Figure 3 – Interaction diagram of DHFR enzyme with TMP (blue) (a) with 8 A˚ surface generated for wild type (pink) and (b) with
mutant (green) depicting change in alignment (c) Ligplot of TMP with wild type (6 A˚) (d) Ligplot of TMP with mutant (6 A˚).
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The current work aimed at checking for mutation in the dfrA
gene fromMtb and analyzing the effect of the mutant enzyme
on inhibitor binding. Thus, the DNA from 20 clinical isolates
of Mtb showing variable resistance to first-line drugs were
used for amplification of the dfrA gene, and one DNA isolate
revealed a point mutation when compared with the wild type
Mtb H37Rv at the 84th position from glutamic acid to glycine,
which led to a surface modification in the 3-D structure of the
protein when analyzed using in silicomethods. Similar studies
carried out by Nosova et al., with other enzymes of Mtb, have
indicated the association of these enzyme mutations, with
resistance to second-line drugs [20]. Resistance to known
drugs was also found to be associated with the DHFR enzyme
mutations in other organisms like Plasmodium vivax [21].
Since the strain with the mutation was found to be resistant
to the first-line drugs Isoniazid, Rifampicin and Streptomycin,
the studies were carried forward to in vitro stages.
The mutant protein was cloned, expressed and studied by
Km determination and for inhibition due to known drugs byemploying an enzyme assay. On comparison with the wild
type, it revealed a peculiarly higher affinity towards the native
substrate DHF and inhibitor TMP. The data with TMP showing
variation co-related with the in silico docking studies. This
data can be justified since a change in the surface geometry
of DHFR has been reported to alter the final binding of TMP
with DHFR [19].
In this experimentation, the inhibitory concentration of
TMP has shown an improvement, indicating that the muta-
tion has no detrimental effect on inhibitor binding as was
expected, but makes the enzyme more susceptible to inhibi-
tion. However, it has been reported that in a number of patho-
gens, resistance towards DHFR inhibitors develops by the
simple accumulation of point mutations in the dfrA gene
[22,23].
Further, the mutant enzyme also showed an increased
affinity towards the native substrate, DHF. These increased
interactions may be due to the two conformational states
showing varying affinities towards anti-folate drugs that have
been proposed for Mtb DHFR [24].
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Point mutations in the target genes have been reported as the
principal mechanism of development of drug resistance in
Mtb [25,26]. Also, mutations in dfrA have been reported to play
a role in Mtb resistance development [27]. Additionally,
Isoniazid (INH) is known to inhibit Mtb DHFR in vitro [28],
and dfrA mutations have also been reported to contribute to
the detection of Isoniazid-resistant Mtb isolates along with
other mutations [29,30]. The Glu84Gly (E84G) mutation in
DHFR conferring increased affinity towards Trimethoprim in
Mtb or other organisms has been reported for the first time
in this paper. Considering the above-mentioned literature
and the fact that the said mutant strain is resistant to
Isoniazid, this point mutation may be proposed to lead to a
variation in the strain which might contribute towards resis-
tance in the future. The in vitro analysis of this particular
mutant in the near future would affirm this assumption.
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